Open AccessNeuropathic pain: targeting the melatonin MT<sub>2</sub> receptor
Author(s) -
Natasha Smith,
Halima Ismail,
Natalie Schellack
Publication year - 2016
Publication title -
south african family practice
Language(s) - English
Resource type - Journals
eISSN - 2078-6204
pISSN - 2078-6190
DOI - 10.4102/safp.v58i4.4528
Subject(s) - neuropathic pain , medicine , melatonin , chronic pain , population , nociception , opioid , guideline , anesthesia , physical therapy , receptor , pathology , environmental health
Neuropathic pain affects a large proportion of the population and reduces a person’s ability to perform optimally. In South Africa, there are a host of factors that hinder the correct diagnosis and treatment of neuropathic pain. Patients suffering from neuropathic pain are treated suboptimally with NSAIDS and opioids as first-line therapy. In 2012, a South African guideline on neuropathic pain was released, which stated that opioid therapy should be reserved for last-line treatment only. More recently, melatonin, commonly known as the neurohormone that regulates the circadian rhythm, has come to light as a therapeutic treatment option in the neuropathic pain setting. Early clinical trials showed a link between melatonin and chronic pain, which includes neuropathic pain. The MT2 receptor has also been specifically linked to the control of neuropathic pain and inflammation.